Schneidewind, L.; Kiss, B.; Zengerling, F.; Uhlig, A.; Klümper, N.; Büttner, T.; Heinzelbecker, J.; Elegeert, T.; Aksoy, C.; Rönnau, C.;
et al. Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy. Biologics 2025, 5, 20.
https://doi.org/10.3390/biologics5030020
AMA Style
Schneidewind L, Kiss B, Zengerling F, Uhlig A, Klümper N, Büttner T, Heinzelbecker J, Elegeert T, Aksoy C, Rönnau C,
et al. Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy. Biologics. 2025; 5(3):20.
https://doi.org/10.3390/biologics5030020
Chicago/Turabian Style
Schneidewind, Laila, Bernhard Kiss, Friedemann Zengerling, Annemarie Uhlig, Niklas Klümper, Thomas Büttner, Julia Heinzelbecker, Thomas Elegeert, Cem Aksoy, Cindy Rönnau,
and et al. 2025. "Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy" Biologics 5, no. 3: 20.
https://doi.org/10.3390/biologics5030020
APA Style
Schneidewind, L., Kiss, B., Zengerling, F., Uhlig, A., Klümper, N., Büttner, T., Heinzelbecker, J., Elegeert, T., Aksoy, C., Rönnau, C., Schiller, T., Hahn, O., Hakenberg, O., Gakis, G., Hoffmann, M., Saar, M., & Kranz, J.
(2025). Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy. Biologics, 5(3), 20.
https://doi.org/10.3390/biologics5030020